Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

BACKGROUND: The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ratio (NER) with outcomes to nivolumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564988/
https://www.ncbi.nlm.nih.gov/pubmed/34732251
http://dx.doi.org/10.1186/s40364-021-00334-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564988/
https://www.ncbi.nlm.nih.gov/pubmed/34732251
http://dx.doi.org/10.1186/s40364-021-00334-4

Ejemplares similares